Inserting Prevnar 13 Into Adult Treatment Guidelines Could Raise Questions For Practitioners
Executive Summary
Uncertainty about the effect of Pfizer’s vaccine in patients that have already had Merck’s Pneumovax 23 could cause problems.
You may also be interested in...
FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial
Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.